EGFR and neoplasm: Indeed, the IdyllaTM assay requires additional sections of FFPE sample and therefore risks exhausting the tumor sample, especially because, contrary to what is recommended by Biocartis, which markets the IdyllaTM EGFR cartridge, we did not perform EGFR genotyping on a single section of 5 μm but on three sections of 20 μm thickness from the paraffin-embedded specimens, because, in our hands, during preliminary tests, we observed that, by following the recommendations of Biocartis, there was a risk of missing out on an EGFR mutation with low allelic frequency.